Vaccination against the major infectious diseases

Comptes Rendus de l'Academie des Sciences - Serie III

Volumn 322, Issue 11, 1999, Pages 943-951

  Plotkin, Stanley A ^a,b  

^a Medical and Scientific Advisor   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CHOLERA VACCINE; HEPATITIS A VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES VACCINE; MUMPS VACCINE; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; SMALLPOX VACCINE; TYPHOID VACCINE; YELLOW FEVER VACCINE;

CELLULAR IMMUNITY; CHOLERA; CONFERENCE PAPER; DIPHTHERIA; DRUG EFFICACY; EPIDEMIC ENCEPHALITIS; HEPATITIS A; HUMAN; IMMUNOLOGICAL MEMORY; INFECTION; INFECTION PREVENTION; INFLUENZA; MAJOR CLINICAL STUDY; MEASLES; MUMPS; POLIOMYELITIS; RABIES; RUBELLA; SMALLPOX; TUBERCULOSIS; TYPHOID FEVER; VACCINATION; VIRUS INFECTION; YELLOW FEVER;

JAPANESE ENCEPHALITIS VIRUS; MYCOBACTERIUM BOVIS BCG; ROTAVIRUS; VARIOLA VIRUS;

EID: 0033231470     PISSN: 07644469     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0764-4469(00)87191-7     Document Type: Conference Paper

References (22)

1. Deschamps D., Observations métaphysiques, première partie, La Vérité Métaphysique, 1750, 1, IV,
2. Plotkin S.L., Plotkin S.A., A short history of vaccination, in: Plotkin S.A., Orenstein W.A. (Eds.), Vaccines, W.B. Saunders, Philadelphia, 1999, pp. 1-12.
3. Fenner, Buller M.L., Mousepox, in: Nathanson N., Ahmed R., Gonzalez-Scarano F. (Eds.), Viral Pathogenesis, Lippincott-Raven, Philadelphia, 1997, p. 541.
4. Ada G., Immunology of vaccines, in: Plotkin S.A., Orenstein W.A. (Eds.), Vaccines, W.B. Saunders, Philadelphia, 1999, pp. 28-39.
5. Henderson D.A., Moss B., Smallpox, in: Plotkin S.A., Orenstein W.A. (Eds.), Vaccines, W.B. Saunders, Philadelphia, 1999, pp. 74-97.
6. Peltola H., Heinonen O.P., Valle M.E.T. et al., The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program, N. Engl. J. Med. 331 (21) (1994) 1397-1402.
7. Chang M.H., Chen C.J., Lai M.L. et al., Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children, N. Engl. J. Med. 336 (26) (1998) 1855-1859.
8. Monath T.P., Yellow fever vaccines: The success of empiricism, pitfalls of application, and transition to molecular vaccinology., in: Plotkin S.A., Fantini B. (Eds.), Vaccinia, Vaccination, and Vaccinology: Jenner, Pasteur and Their Successors, Elsevier, Paris, 1996, pp. 157-182.
9. Plotkin S.A., Murdin A., Vidor E., Polio vaccine - Inactivated, in: Plotkin S.A., Orenstein W.A. (Eds.), Vaccines, W.B. Saunders, Philadelphia, 1999, pp. 345-363.
10. Oostvogel P.M., Wijngaarden J.K., Van der Avoort H.G.A.M. et al., Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-1993, N. Engl. J. Med. 344 (1994) 665-670.
11. Govaert M.E., Thijs C.T., Masurel N. et al., The efficacy of influenza vaccination in elderly individuals,JAMA 272 (1994) (21) 1661-1665.
12. Belshe R., Iacuzio D., Mendelman P. et al., Efficacy of a trivalent live attenuated intranasal influenza vaccine in children, 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998, p. 663 (abstract).
13. Clark F.H., Offit P.A., Glass R., Rotavirus, in: Plotkin S.A., Orenstein W.A. (Eds.), Vaccines, W.B. Saunders, Philadelphia, 1999, pp. 941-1005.
14. Baltazard M., Ghodssi M., Prevention de la rage humaine,Rev. Immunol. 17 (1953) 366-371.
15. Rosenstein N., Levine O.,Taylor J.P. et al., Efficacy of meningococcal vaccine and barriers to vaccination, JAMA 279 (1998) 435-439.
16. Hargreaves R.M., Slack M.P.E., Howard A.J. et al., Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme,Br. J. Med. 312 (1996) 160-161.
17. Black S., Shinefield H., Ray P. et al., Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37 000 infants and children: Results of the Northern California kaiser permanente efficacy trial,38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, 1998, p. 23 (abstract).
18. Mortimer E.A., Wharton M., Diphtheria, in: Plotkin S.A., Orenstein W.A. (Eds.), Vaccines, W.B. Saunders, Philadelphia, 1999, pp. 140-157.
19. Demicheli V., Rivetti D., Deeks J.J. et al., The effectiveness and safety of vaccines against human anthrax: A systematic review, Vaccine 16 (9) (1998) 880-884.
20. Plotkin S.A., Cadoz M., The acellular pertussis vaccine trials: An interpretation,Pediatr. Infec. Dis. J. 16 (1997) 508-517.
21. O'Shea S., Best J.M., Banatvala J.E., Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus, J. Infect. Dis. 148 (4) (1983) 639-647.
22. Zepp F., Schmitt J., Kaufhold A. et al., Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: Plain Haemophilis influenzae type b- PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine, Eur. J. Pediatr. 156 (1997) 18-24.